Utilising deep learning algorithms, the AI-powered solution automates the real-time detection of foetal ultrasound views. Credit: megaflopp / Shutterstock.

利用深度学习算法，这款人工智能解决方案实现了胎儿超声视图的实时自动检测。来源：megaflopp / Shutterstock。

The US Food and Drug Administration (FDA) has granted 510(k) clearance to DeepEcho’s foetal ultrasound analysis platform.

美国食品药品监督管理局 (FDA) 已授予 DeepEcho 的胎儿超声分析平台 510(k) 许可。

This decision allows the company to enhance prenatal care and expand access to this technology.

这一决定使公司能够加强产前护理并扩大对该技术的使用。

Go deeper with GlobalData

深入探索GlobalData

Innovation in Healthcare: Doppler Ultrasound Imaging

医疗保健创新：多普勒超声成像

Innovation in Healthcare: Endoscopic Ultrasound Tomography

医疗创新：内窥镜超声断层扫描

Data Insights

数据洞察

The gold standard of business intelligence.

商业智能的黄金标准。

Utilising deep learning algorithms, the AI-powered solution automates real-time detection of foetal ultrasound views, aiding healthcare professionals by improving diagnostic accuracy and image evaluations.

利用深度学习算法，这款人工智能驱动的解决方案实现了胎儿超声视图的实时自动检测，通过提高诊断准确性和图像评估来辅助医疗专业人员。

The platform’s approach includes segmentation of structures for foetal biometry and amniotic fluid volume evaluation, offering a standardised analysis of foetal structures.

该平台的方法包括对胎儿生物测量和羊水体积评估的结构分割，提供胎儿结构的标准化分析。

DeepEcho focuses on foetal ultrasound diagnostics, with a presence across three continents: Europe, Africa, and the US.

DeepEcho 专注于胎儿超声诊断，在欧洲、非洲和美国三大洲开展业务。

The solution was developed by the company’s team, comprising AI scientists, physicians, and medical imaging experts.

该解决方案由公司的团队开发，团队成员包括人工智能科学家、医生和医学影像专家。

GlobalData Strategic Intelligence

全球数据战略情报

US Tariffs are shifting - will you react or anticipate?

美国关税正在变化——你会做出反应还是提前预料？

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

不要让政策变化让你措手不及。通过实时数据和专家分析保持主动性。

By GlobalData

由GlobalData提供

Learn more about Strategic Intelligence

了解有关战略情报的更多信息

DeepEcho chief medical officer and co-founder Dr Saad Slimani said: “This milestone underscores the power of combining AI with clinical expertise to solve some of the most critical problems in healthcare.

DeepEcho首席医疗官兼联合创始人萨阿德·斯利马尼博士表示：“这一里程碑凸显了将人工智能与临床专业知识相结合以解决医疗保健领域一些最关键问题的力量。

“With this FDA clearance, we are one step closer to making early, accurate prenatal diagnosis universally accessible and helping clinicians deliver better outcomes for families.”

“随着FDA的批准，我们离实现普遍可及的早期、准确的产前诊断又近了一步，并帮助临床医生为家庭带来更好的结果。”

DeepEcho noted that it is creating next-generation solutions that utilise AI to detect biomarkers.

DeepEcho 指出，它正在创建利用人工智能检测生物标志物的下一代解决方案。

These advancements aim to facilitate the early prediction of complex conditions like preeclampsia, a major cause of maternal and neonatal morbidity and death.

这些进展旨在促进对先兆子痫等复杂病症的早期预测，这是导致孕产妇和新生儿发病及死亡的主要原因。

DeepEcho CEO and co-founder Youssef Bouyakhf said: “Our FDA clearance is a pivotal achievement, validating the rigour of our technology and the quality and safety of our product at DeepEcho.

DeepEcho 首席执行官兼联合创始人尤瑟夫·布亚赫夫表示：“我们获得 FDA 批准是一项关键的成就，验证了 DeepEcho 技术的严谨性以及我们产品的质量和安全性。

“We are extremely excited about the potential behind our current solution and the very ambitious plans we have for DeepEcho with more advanced features that we will bring to market in the near future.”

“我们对当前解决方案的潜力以及我们对DeepEcho的非常宏大的计划感到无比兴奋，未来我们将推出更多高级功能。”